|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
|
18559552 |
2008 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore, in a series of gastric adenocarcinomas we studied the association of p27(KIP1) expression with H. pylori genotype (vacA, cagA, cagE and virB11) and the involvement of C-MYC in this process.
|
20059402 |
2010 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We demonstrate that IBD-associated intestinal adenocarcinomas have a high frequency of c-MYC amplification that is associated with mucinous and signet ring cell differentiation.
|
29788391 |
2018 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
LHGDN |
c-myc amplification is frequent in esophageal adenocarcinoma and correlated with the upregulation of VEGF-A expression.
|
16984727 |
2006 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
K-RAS point mutation, as well as amplification of C-MYC and C-ERBB2 were searched in 84 primary colon adenocarcinomas resected with curative intent.
|
15493579 |
2004 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Transgenic MYC expression drives invasive adenocarcinomas in the murine prostate.
|
22585994 |
2012 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.
|
16886612 |
2006 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
c-MYC gain (but not chromosome 8 gain or c-MYC amplification) was an independent poor-prognostic factor for DFS and OS in lung adenocarcinomas, both in full cohort and stage I cancer, and possibly for DFS in EGFR-mutant adenocarcinomas.
|
24809777 |
2014 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Considering that α1 subunit/<i>ITGA1</i> expression is correlated with MYC in more than 70% of colon adenocarcinomas, we postulated that the integrin α1β1 has a pro-tumoral contribution to CRC.
|
28933766 |
2017 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
|
1552612 |
1992 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dual-color fluorescence in situ hybridization (FISH) for the C-MYC gene and chromosome 8 centromere was performed in 11 gastric adenocarcinomas.
|
16309200 |
2006 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased copy number of the ERBB2 (1 of 22), GATA4 (1 of 22), KRAS (2 of 22), C-MYC (1 of 22), CCNE1 (2 of 22), and CCND1 (2 of 22) genes was also observed in one or more Barrett's adenocarcinomas with HGD.
|
14581353 |
2003 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The aim of the present study is to determine the presence and molecular integrity of high-risk HPV types in colorectal adenocarcinomas and to assess whether viral DNA is related to common proto-oncogene alterations, such as k-ras mutations and c-myc gene amplification, in colorectal cancer.
|
20232185 |
2010 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In the present study, amplification of the proto-oncogene c-myc was determined by means of differential polymerase chain reaction analysis of metaplastic specialized epithelium, low-grade dysplasia, high-grade dysplasia, and invasive adenocarcinoma obtained by microscopic dissection of 43 esophagectomy specimens.
|
11392879 |
2001 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We show that deregulated c-MYC expression in this inducible system results in the formation of invasive mammary adenocarcinomas, many of which fully regress following c-MYC deinduction.
|
11175856 |
2001 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The c-myc gene was amplified 5-7-fold in two adenocarcinomas, the H-ras gene 3 5-fold in one adenocarcinoma, while the K-ras and the neu gene were amplified in lung metastases from a colorectal and a breast cancer primary respectively.
|
2547415 |
1989 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Interference of mouse polyomavirus with the c-myc gene and its product in mouse mammary adenocarcinomas.
|
12851682 |
2003 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Firstly, lentivirus-mediated transduction of KRAS(G12V), MYC and human papillomavirus 16 (HPV16) E6/E7 under the control of a tetracyclin-inducible promoter efficiently immortalized and transformed primary HPDECs, which gave rise to adenocarcinomas subcutaneously in an immune-deficient mouse xenograft model, depending on expression of the four genes.
|
24858378 |
2014 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.
|
26432044 |
2015 |
|
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin.
|
12209953 |
2002 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Whereas the frequency of MYC amplification was similar to adenocarcinoma (10.5% versus 4%, P = .2), the frequency of PTGER4 amplification was higher than adenocarcinoma (10.5% versus 0.3%, P = .01).
|
28899736 |
2018 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In the context of compound Pten/p53 heterozygosity, c-MYC-initiated cells progress to prostatic intraepithelial neoplasia (mPIN) and adenocarcinoma lesions with marked heterogeneity within the same prostate glands.
|
21685943 |
2012 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
LHGDN |
Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver.
|
17587243 |
2007 |
|
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
LHGDN |
MYC and gastric adenocarcinoma carcinogenesis.
|
18932273 |
2008 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
By contrast, mice with both alterations (Hoxb13-MYC∣Hoxb13-Cre∣Pten(Fl/Fl), hereafter, BMPC mice) developed lethal adenocarcinoma with distant metastases and widespread genome CNAs that were independent of forced disruption of Tp53 and telomere shortening.
|
26554830 |
2016 |